Descrizione del progetto
La biodecontaminazione per evitare la diffusione di infezioni negli ospedali
Il centro europeo per la prevenzione e il controllo delle malattie stima che ogni anno, nei paesi dell’UE, 3,8 milioni di persone contraggono un’infezione correlata all’assistenza ospedaliera nei reparti di terapia intensiva. La biodecontaminazione è la soluzione migliore per evitare la diffusione di batteri o di virus letali, eliminando il 99,999 % di microrganismi. Tuttavia, la biodecontaminazione non è ampiamente adottata. Il progetto DELOX, finanziato dall’UE, ha sviluppato un agente di decontaminazione innovativo basato su una formulazione solida, dryVHP, che rilascia vapore di acqua ossigenata a basse temperature (60 °C). Tale proprietà riduce la potenza assorbita, i costi dell’attrezzatura e consente la produzione di un dispositivo più compatto e più solido. L’attrezzatura di DELOX è l’unica soluzione accessibile, compatta e altamente efficiente sul mercato.
Obiettivo
Hospital acquired infections affect 1 in every 14 patients, a number that goes as high as 1 in every 5 patients when considering intensive care units. Delox has the potential to change that.
Decontamination is performed using several different methods and technologies nowadays. The most relevant one is sterilization, which is an expensive procedure, typically only affordable for very large hospital in well developed countries or outsourced to a specialized firm. In the laboratory and health context the use of Formaldehyde is also still frequent – because it is price competitive – but it is toxic and far from perfect.
The state-of-the-art technology is VHP (Vaporized Hydrogen Peroxide) which is costly, expensive and energy intensive, as it requires heating Hydrogen Peroxide to 130oC. Our formulation – dryVHP – differs by needing to be heat up to only 60 oC to produce the same effect. It is also significantly cheaper.
Delox will be initially brought to market for use in laboratory equipment (<2 m3) and then a more powerful and adjustable version will be launched to address the Hospital, clinics and food sectors.
It is the business outcome of more than 6 years of research and it has the potential to disrupt the bio-decontamination and sterilization market, having gathered interest from several large stakeholders, and received awards and recognition.
We have also already raised 371.8k€ from VC (300k), awards (10k), public startup vouchers (11k€) and the European Space Agency.
Within this Phase 1 we will prepare the next steps of our development (technical and commercial) but also validate our technology by preparing pilots with relevant players to demonstrate in real environment and prepare robust case studies that will boost market acceptance.
By bringing to the market a non-toxic bio-decontamination solution that is cheap, effective, rugged and non-toxic Delox will make bio-decontamination affordable and accessible everywhere.
Campo scientifico
Programma(i)
Argomento(i)
Invito a presentare proposte
Vedi altri progetti per questo bandoBando secondario
H2020-SMEInst-2018-2020-1
Meccanismo di finanziamento
SME-1 - SME instrument phase 1Coordinatore
2645 449 CASCAIS
Portogallo
L’organizzazione si è definita una PMI (piccola e media impresa) al momento della firma dell’accordo di sovvenzione.